An Update on Approved and Innovative Therapeutic Approaches to Combatting Influenza Viruses

Medical News: Influenza remains a significant global health threat, causing seasonal epidemics and posing the risk of pandemics. Currently, countries like the United States and China are facing an exponential surge in influenza infections that is also seeing hospitalizations and deaths rise. Despite advances in vaccine development and antiviral treatments, the virus continues to evolve, necessitating new therapeutic approaches. Researchers worldwide are working to develop innovative antiviral strategies that can effectively combat influenza while reducing the risk of drug resistance. This Medical News report provides an overview of the latest advancements in antiviral therapies, including both approved drugs and promising experimental treatments.


An Update on Approved and Innovative Therapeutic Approaches to Combatting Influenza Viruses

Current Clinical Management of Influenza
The primary strategy for treating influenza involves antiviral drugs that target different stages of the virus’s replication cycle. The first class of anti-influenza drugs, amantadine and rimantadine, were approved in the 1980s. These drugs target the viral M2 ion channel, preventing viral uncoating. However, due to widespread drug resistance, their clinical use has been largely discontinued.
 
The second class of antiviral agents includes neuraminidase inhibitors (NAIs) such as oseltamivir (Tamiflu), zanamivir (Relenza), peramivir (Rapivab), and laninamivir (Inavir). These drugs prevent the release of new viral particles from infected cells, thereby limiting the spread of the virus. NAIs are generally effective against both influenza A and B, but their efficacy depends on early administration, preferably within 48 hours of symptom onset.
 
More recently, polymerase inhibitors like baloxavir marboxil (Xofluza) have been introduced. Baloxavir inhibits the viral polymerase acidic (PA) protein, which is essential for viral replication. Unlike NAIs, baloxavir requires only a single dose, making it a convenient treatment option. However, some strains of influenza have shown reduced susceptibility to baloxavir, highlighting the need for alternative therapies.
 
Emerging Antiviral Strategies
-Virus-Directed Drugs
New antiviral agents targeting viral proteins are under development to combat drug-resistant influenza strains. Researchers are focusing on inhibitors that disrupt the function of hemagglutinin (HA), a key viral surface protein involved in cell entry. Compounds that prevent HA maturation have shown promising results in preclinical studies.
 
Additionally, nucleoprotein (NP) inhibitors are being explored as potential treatments. Nucleoproteins play a crucial role in viral genome replication, and disrupting their function can halt viral proliferation. Experimental drugs like nucleozin and FA-6005 have demonstrated efficacy against multiple influenza strains, including drug-resistant variants.
 
Another approach involves targeting the viral RNA polymerase complex, which is crucial fo r viral replication. Drugs such as pimodivir (VX-787) and favipiravir (Avigan) work by interfering with different components of the polymerase machinery. Pimodivir specifically targets the PB2 subunit, while favipiravir acts as a nucleoside analog, causing lethal mutations in the viral genome.
 
-Host-Directed Drugs
Rather than targeting the virus directly, some therapies aim to modify host cell factors that the virus relies on for replication. This approach reduces the likelihood of viral resistance. For example, drugs like naproxen, which inhibit the nuclear export of viral ribonucleoproteins, have shown potential in early trials.
 
Another promising avenue involves boosting the host immune response.
Interferon-based therapies enhance the body’s natural antiviral defenses. Researchers are also investigating small molecules that activate RIG-I and Toll-like receptors (TLRs), which are part of the innate immune system. These agents can stimulate antiviral gene expression, helping to suppress viral replication.
 
Statins such as atorvastatin and fibrates are being explored for their potential to modulate host lipid metabolism, thereby reducing viral replication. Additionally, calcium channel blockers like diltiazem have been repurposed to target host pathways essential for viral entry and replication.
 
Combination Therapies
Combining multiple antiviral agents is emerging as a powerful strategy to improve treatment efficacy and reduce the risk of resistance. Studies have shown that combining oseltamivir with anti-inflammatory drugs like celecoxib can enhance clinical outcomes. Similarly, a triple combination of oseltamivir, clarithromycin, and naproxen demonstrated superior efficacy in reducing symptom duration and mortality in hospitalized influenza patients.
 
Researchers are also testing combinations of virus-directed and host-directed therapies. For example, pairing baloxavir with immune-boosting agents has shown promise in preclinical studies. These combination approaches could become the future standard of care for severe influenza infections.
 
Monoclonal antibodies (mAbs) such as CR6261, MHAA4549A, and VIS-410 are being developed as combination therapies to enhance immune responses against the virus. These antibodies bind to conserved regions of the virus, reducing its ability to mutate and escape treatment.
 
Promising Preclinical Research
Beyond the therapies currently in clinical trials, researchers are exploring novel antiviral mechanisms in laboratory settings. Some experimental approaches include:
 
-Targeted Protein Degradation: Scientists are developing molecules that selectively degrade viral proteins, preventing the virus from replicating.
Nanoparticle-Based Drug Delivery: Nanotechnology is being used to enhance the bioavailability and targeted delivery of antiviral compounds, reducing side effects and improving efficacy.
 
-RNA Interference (RNAi) Therapies: Small interfering RNAs (siRNAs) are being designed to target viral genes, shutting down their expression and preventing replication.
 
-Gene Editing: CRISPR-based approaches are being explored to directly edit viral RNA and prevent infection at the genetic level.
 
Challenges and Future Directions
Despite these advancements, several challenges remain in the development of new influenza therapies. The rapid mutation rate of influenza viruses necessitates continuous monitoring and adaptation of antiviral strategies. Additionally, drug affordability and accessibility remain key concerns, particularly in low-resource settings.
 
Regulatory approval processes can also slow the introduction of novel treatments. However, ongoing global collaboration among research institutions and pharmaceutical companies is accelerating the development of new antiviral agents.
 
Conclusion
Influenza continues to pose a significant public health challenge, but advances in antiviral therapy offer hope for more effective treatments. The combination of virus-directed and host-directed drugs, along with innovative delivery mechanisms, represents a promising path forward. Future research will focus on optimizing these therapies to enhance efficacy, minimize resistance, and improve patient outcomes.
 
The study review findings were published in the peer-reviewed journal: Cellular and Molecular Life Sciences.
https://link.springer.com/article/10.1007/s00018-025-05611-1
 
For the latest Influenza News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/probenecid-shows-promise-against-respiratory-virus-human-metapneumovirus-hmpv
 
https://www.thailandmedical.news/news/probenecid-found-to-inhibit-respiratory-syncytial-virus-replication
 
https://www.thailandmedical.news/news/new-approach-using-traditional-japanese-medicine-and-minocycline-for-influenza-treatment
 
https://www.thailandmedical.news/news/alkylamides-from-echinacea-shows-promising-effects-against-respiratory-viruses
 
https://www.thailandmedical.news/news/promising-hope-from-sturgeon-oil-for-respiratory-health
 
https://www.thailandmedical.news/news/korean-researchers-find-that-the-herb-angelica-tenuissima-nakai-shows-promise-in-fighting-influenza-a